10-1-2813 US producer questionnaire

OMB No. 3117-0016/USITC No. 10-1-2813; Expiration Date: 6/30/2011
(No response is required if currently valid OMB control number is not displayed)

U.S. PRODUCERS’ QUESTIONNAIRE
CHLOROPICRIN FROM CHINA

This questionnaire must be received by the Commission by no later than DECEMBER 16, 2009
See page 4 of the Instruction Booklet for filing instructions.
The information called for in this questionnaire is for use by the United States International Trade Commission in
connection with its review of the antidumping duty order concerning chloropicrin from China (Inv. No. 732-TA-130
(Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of
1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to
compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm
Address
State

City

Zip Code

World Wide Web address
Has your firm produced chloropicrin (as defined in the instruction booklet) at any time since January 1, 2006?

NO

(Sign the certification below and promptly return only this page of the questionnaire to the Commission)

YES

(Read the instruction booklet carefully, complete all parts of the questionnaire, and return the entire
questionnaire to the Commission so as to be received by the date indicated above)

CERTIFICATION
I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge
and belief and understand that the information submitted is subject to audit and verification by the Commission.
By means of this certification I also grant consent for the Commission, and its employees and contract personnel, to use the
information provided in this questionnaire and throughout this review in any other import-injury investigations or reviews
conducted by the Commission on the same or similar merchandise.
I acknowledge that information submitted in this questionnaire response and throughout this review may be used by the
Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or
maintaining the records of this review or related proceedings for which this information is submitted, or in internal audits and
investigations relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all
contract personnel will sign non-disclosure agreements.

Name of Authorized Official

Title of Authorized Official
Phone: (

Date

)

Signature

E-mail address
Fax (

)

Business Proprietary
U.S. Producers’ Questionnaire – Chloropicrin from China (731-TA-130 (Third Review))

Page 2

PART I.—GENERAL INFORMATION
The questions in this questionnaire have been reviewed with market participants to ensure that issues of
concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as
possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response,
including the time for reviewing instructions, searching existing data sources, gathering the data needed,
and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden
estimate or any other aspect of this collection of information, including suggestions for reducing the
burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW,
Washington, DC 20436.
I-1a.

OMB statistics.--Please report below the actual number of hours required and the cost to your
firm of preparing the reply to this questionnaire and completing the form.
hours

dollars

I-1b.

OMB feedback.--We are interested in any comments you may have for improving this
questionnaire in general or the clarity of specific questions. Please attach such comments to your
response or send them to the above address.

I-2.

Establishments covered.--Provide the name and address of establishment(s) covered by this
questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is
publicly traded, please specify the stock exchange and trading symbol.

I-3.

Support for continuation of order.--Do you support or oppose continuation of the antidumping
and/or countervailing duty order currently in place for chloropicrin from the following country?
China

Support

Oppose

Take no position

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 3

PART I.--GENERAL INFORMATION--Continued
I-4.

Ownership.--Is your firm owned, in whole or in part, by any other firm?
No

Yes--List the following information.

Firm name

I-5.

I-6.

Address

Extent of ownership

Related SUBJECT importers/exporters.--Does your firm have any related firms, either
domestic or foreign, which are engaged in importing chloropicrin from China into the United
States or which are engaged in exporting chloropicrin from China to the United States?
No

Yes--List the following information.

Firm name

Address

Affiliation

Related NONSUBJECT importers/exporters.--Does your firm have any related firms, either
domestic or foreign, which are engaged in importing chloropicrin from countries other than China
into the United States or which are engaged in exporting chloropicrin from countries other than
China to the United States?
No

Yes--List the following information.

Firm name and country

Address

Affiliation

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 4

PART I.--GENERAL INFORMATION--Continued
I-7.

I-8.

Related producers.--Does your firm have any related firms, either domestic or foreign, which
are engaged in the production of chloropicrin?
No

Yes--List the following information.

Firm name

Address

Affiliation

Business plan.--In Parts II and IV of this questionnaire we request a copy of your company’s
business plan. Does your company or any related firm have a business plan or any internal
documents that describe, discuss, or analyze expected market conditions for chloropicrin?
No

Yes--Please provide the requested documents. If you are not providing the
requested documents, please explain why not.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 5

PART II.--TRADE AND RELATED INFORMATION
Further information on this part of the questionnaire can be obtained from Cynthia Trainor (202-2053354; [email protected]). Supply all data requested on a calendar-year basis.
II-1.

Contact information (Trade).--Who should be contacted regarding the requested trade and
related information?
Company contact:
Name and title
(
)
Phone number

II-2.

E-mail address

Changes in operations.--Please indicate whether your firm has experienced any of the following
changes in relation to the production of chloropicrin since January 1, 2006?
(check as many as appropriate)
plant openings ..........................

plant closings............................

relocations ................................

expansions ................................

acquisitions...............................

consolidations...........................

prolonged shutdowns or
production curtailments .................
revised labor agreements ..........

other (e.g., technology) ............

(please describe)

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 6

PART II.--TRADE AND RELATED INFORMATION--Continued
II-3.

Anticipated changes in operations.--Does your firm anticipate any changes in the character of
your operations or organization (as noted above) relating to the production of chloropicrin in the
future?
No

II-4.

Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address this
issue. Include in your response a specific projection of your firm’s
capacity to produce chloropicrin (in 1,000 pounds) for 2008 and
2009.

Anticipated changes in operations in the event the order is revoked.--Would your firm
anticipate any changes in the character of your operations or organization (as noted above)
relating to the production of chloropicrin in the future if the antidumping duty order on
chloropicrin from China were to be revoked?
No

Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address this
issue.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 7

PART II.--TRADE AND RELATED INFORMATION--Continued
II-5.

Same equipment, machinery, and workers.--Has your firm since 2006 produced, or does your
firm anticipate producing in the future, other products on the same equipment and machinery
used in the production of chloropicrin and/or using the same production and related workers
employed to produce chloropicrin?
No

Yes--List the following information and report your firm’s combined
production capacity and production of these products and chloropicrin
in the periods indicated.

Product

Basis for allocation of capacity and
employment data (indicate if different)

Period

(Quantity in 1,000 pounds)
Item

2006

2007

2008

Overall Production Capacity
Production of:
Chloropicrin
Other product 1
Other product 2

II-6.

Constraints on production.--Please describe the constraint(s) that set the limit(s) on your
production capacity.

II-7.

Production shifting.--Is your firm able to switch production between chloropicrin and other
products in response to a relative change in the price of chloropicrin vis-a-vis the price of other
products, using the same equipment and labor?
No

Yes--Please identify the other products, the approximate time and cost
involved in switching, and the minimum relative price change required
for your firm to switch production to or from chloropicrin.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 8

PART II.--TRADE AND RELATED INFORMATION--Continued
II-8.

Trade data.--Report your firm’s production capacity, production, shipments, inventories, and
employment related to the production of chloropicrin in your U.S. establishment(s) during the
specified periods. (See definitions in the instruction booklet.)
Quantity (in 1,000 pounds) and value (in $1,000)
Calendar year
Item

2006

2007

January-September
2008

2008

2009

1

Average production capacity
(quantity) (A)

Beginning-of-period inventories
(quantity) (B)
Production (quantity) (C)
U.S. shipments:
Commercial shipments:
quantity (D)
value (E)
Internal consumption:2
quantity (F)
value (G)
Transfers to related firms:2
quantity (H)
value (I)
Export shipments:3
quantity (J)
value (K)
End-of-period inventories
(quantity) (L)
Channels of distribution:
U.S. shipments to distributors
(quantity) (M)
U.S. shipments to end users
(quantity) (N)
Employment data:
Average number of PRWs
(number) (O)
Hours worked by PRWs (1,000
hours) (P)
Wages paid to PRWs (value) (Q)
1

The production capacity (see definitions in instruction booklet) reported is based on operating
hours per week,
weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported
capacity (use additional pages as necessary).
2

Internal consumption and transfers to related firms should be valued at fair market value. In the event that you use a
different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using
that basis for each of the periods noted above:
3

Identify your principal export markets:

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 9

PART II.--TRADE AND RELATED INFORMATION--Continued
II-9.

Reconciliation of trade data.--

(a)

Please note that the quantities reported in question II-10 should reconcile as follows in
each period (i.e., in each column):
Reconciliation
B+C–D–F–H–J=L
D+F+H=M+N

(b)

Yes

No--Please

Yes

No--Please

Please note that the quantities reported for end of period inventories should equal the
beginning of period inventories reported in the subsequent calendar year (i.e., line L of
year 2006 should equal line B of year 2004). Do these data reconcile for each adjacent
calendar year?
Yes.

II-10.

Do these data reconcile?
explain
Do these data reconcile?
explain

No--Please explain.

Transfers to related firms.--If you reported transfers to related firms in question II-8, please
indicate the nature of the relationship between your firm and the related firms (e.g., joint venture,
wholly owned subsidiary), whether the transfers were priced at market value or by a non-market
formula, whether your firm retained marketing rights to all transfers, and whether the related
firms also processed inputs from sources other than your firm.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 10

PART II.--TRADE AND RELATED INFORMATION--Continued
II-11.

Purchases.--Other than direct imports, has your firm otherwise purchased chloropicrin since
January 1, 2006? (See definitions in the instruction booklet.)
No

Yes-- Please indicate the reasons for your purchases (if your reasons differ by
source, please elaborate) and report the quantity and value of such
purchases below for the specified periods

Reasons:
Quantity (in 1,000 pounds) and value (in $1,000)
Item

2006

2007

2008

PURCHASES FROM U.S.
1
IMPORTERS OF CHLOROPICRIN
FROM.—
CHINA:
quantity
value
All other countries:
quantity
value
PURCHASES FROM DOMESTIC
2
PRODUCERS:
quantity
value
PURCHASES FROM OTHER
SOURCES:
quantity
Value
1
Please list the name of the importer(s) from which you purchased this product. If your suppliers differ by
source, please identify the source for each listed supplier.

2

Please list the name of the domestic producer(s) from which you purchased this product.

II-12.

Toll production.--Since January 1, 2006, has your firm been involved in a toll agreement (see
definition in the instruction booklet) regarding the production of chloropicrin?
No

II-13.

Yes--Name firm(s):

.

FTZ.--Does your firm produce chloropicrin in a foreign trade zone (FTZ)?
No

Yes--Identify FTZ(s):

.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 11

PART II.--TRADE AND RELATED INFORMATION--Continued
II-14.

Direct imports.--Since January 1, 2006, has your firm imported chloropicrin?
No

Yes--COMPLETE AND RETURN A U.S. IMPORTERS’
QUESTIONNAIRE

II-15.

Effect of order.--Describe the significance of the existing antidumping duty order covering
imports of chloropicrin from China in terms of its effect on your firm’s production capacity,
production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash
flow, capital expenditures, research and development expenditures, and asset values. You may
wish to compare your firm’s operations before and after the imposition of the order.

II-16.

Likely effect of revocation of order.--Would your firm anticipate any changes in its production
capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs,
profits, cash flow, capital expenditures, research and development expenditures, or asset values
relating to the production of chloropicrin in the future if the antidumping duty order on
chloropicrin from China were to be revoked?
No

Yes--Supply details as to the time, nature, and significance of such changes
and provide underlying assumptions, along with relevant portions of
business plans or other supporting documentation for any trends or
projections you may provide.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 12

PART III.--FINANCIAL INFORMATION
Address questions on this part of the questionnaire to David Boyland (202-708-4725;
[email protected]).
III-1.

Contact information (Financial).--Who should be contacted regarding the requested financial
information?
Company contact:
Name and title
(
)
Phone number

III-2.

E-mail address

Accounting system.--Briefly describe your financial accounting system.
A.

When does your fiscal year end (month and day)?
If your fiscal year changed during the period examined, explain below:

B.1.

Describe the lowest level of operations (e.g., plant, division, company-wide) for which
financial statements are prepared that include subject merchandise:

2.
3.

4.

Does your firm prepare profit/loss statements for the subject merchandise:
Yes
No
How often did your firm (or parent company) prepare financial statements (including
annual reports, 10Ks)? Please check relevant items below.
Audited,
unaudited,
annual reports,
10Ks,
10 Qs,
Monthly,
quarterly,
semi-annually,
annually
Accounting basis:
GAAP,
cash,
tax, or
other comprehensive
(specify)
Note: The Commission may request that your company submit copies of its financial statements,
including internal profit-and-loss statements for the division or product group that includes
chloropicrin, as well as those statements and worksheets used to compile data for your firm’s
questionnaire response.

III-3.

Cost accounting system.--Briefly describe your cost accounting system (e.g., standard cost, job
order cost, etc.).

III-4.

Allocation basis.-Briefly describe your allocation basis, if any, for COGS, SG&A, and interest
expense and other income and expenses.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 13

PART III.--FINANCIAL INFORMATION--Continued
III-5.

Other products.--Please list any other products you produced in the facilities in which you
produced chloropicrin, and provide the share of net sales accounted for by these other products in
your most recent fiscal year:
Products

III-6.

Raw materials from related firms.--Does your company purchase inputs (raw materials, labor,
energy, or any other services) used in the production of chloropicrin from any related company
whose financial statements are ultimately consolidated with the financial statements of your firm?
Yes--Continue to question III-7 below

III-7.

Share of sales

No--Continue to question III-10 below

Inputs from related firms.--In the space provided below, identify the inputs used in the
production of chloropicrin that your firm receives from related parties whose financial statements
are consolidated with the financial statements of your firm.
Input

Related party

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 14

PART III.--FINANCIAL INFORMATION--Continued
III-8.

Inputs from related firms at cost.--All intercompany profit on inputs purchased from related
parties that is eliminated pursuant to formal financial statement consolidation should also be
eliminated from the costs reported to the Commission in question III-10 (i.e., costs reported in
question III-10, to the extent that they reflect inputs purchased from related parties, should only
reflect the related party’s cost and not include an associated profit component). Reasonable
methods for determining and eliminating the associated profit on inputs purchased from related
parties are acceptable.
Has your firm complied with the Commission’s instructions regarding costs associated with
inputs purchased from related parties?
Yes

III-9.

No—Please contact David Boyland (202-708-4725; [email protected]).

Nonrecurring charges.--For each annual and interim period for which financial results are
reported in question III-10, please indicate in the schedule below the specific nonrecurring
charges, the particular expense/cost line items from question III-10 where the associated charges
are included, a brief description of the charges, and the associated values (in $1,000).
Nonrecurring charges would include, but are not limited to, items such as asset write-offs and
accelerated depreciation due to restructuring of the company’s chloropicrin operations.
Fiscal years ended-Item

January-September
2008

2009

Non-recurring charges: (In the far left column please provide a brief description of each nonrecurring charge and
indicate the particular expense/cost line items where the associated charges are included in question III-10.)
1.
2.
3.
4.
5.
6.
7.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 15

PART III.--FINANCIAL INFORMATION--Continued
III-10. Operations on chloropicrin.--Report the revenue and related cost information requested below
on the chloropicrin operations of your U.S. establishment(s).1 Do not report resales of products.
Note that internal consumption and transfers to related firms must be valued at fair market value
and purchases from related firms must be at cost.2 Provide data for your three most recently
completed fiscal years in chronological order from left to right. If your firm was involved in
tolling operations (either as the toller or as the tollee) please contact David Boyland at (202) 7084725 before completing this section of the questionnaire.
Quantity (in 1,000 pounds) and value (in $1,000)
Fiscal years ended-Item
Net sales quantities:3
Commercial sales
Internal consumption
Transfers to related firms
Total net sales quantities
Net sales values:3
Commercial sales
Internal consumption
Transfers to related firms
Total net sales values
Cost of goods sold (COGS):4
Nitromethane
Other raw materials
Total raw materials
Direct labor
Other factory costs
Total COGS
Gross profit or (loss)
Selling, general, and administrative
(SG&A) expenses:
Selling expenses
General and administrative expenses
Total SG&A expenses
Operating income (loss)
Other income and expenses:
Interest expense
All other expense items
Continued Dumping and Subsidy Offset Act
5
funds received

All other income items
All other income or expenses, net
Net income or (loss) before income taxes
Depreciation/amortization included above
1

Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please indicate the amount of profits or (losses) on inputs from related firms that were eliminated pursuant question III-8:
Year 2
Year 3
.
Year 1
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment
quantities and values reported in Part II of this questionnaire.
4
COGS should include costs associated with internal consumption and transfers to related firms.
5
Please report funds received under this act in the period(s) in which they were received. Do not report these funds as an offset to
operating expenses.
2

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 16

PART III.--FINANCIAL INFORMATION--Continued

III-10. Operations on chloropicrin.--Continued
Quantity (in 1,000 pounds) and value (in $1,000)
Item

January-September 2008

January-September 2009

3

Net sales quantities:
Commercial sales

Internal consumption
Transfers to related firms
Total net sales quantities
Net sales values:3
Commercial sales
Internal consumption
Transfers to related firms
Total net sales values
Cost of goods sold (COGS):4
Raw materials
Direct labor
Other factory costs
Total COGS
Gross profit or (loss)
Selling, general, and administrative (SG&A)
expenses:
Selling expenses
General and administrative expenses
Total SG&A expenses
Operating income (loss)
Other income and expenses:
Interest expense
All other expense items
Continued Dumping and Subsidy Offset Act funds
5
received

All other income items
All other income or expenses, net
Net income or (loss) before income taxes
Depreciation/amortization included above
1

Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
Please indicate the amount of profits or (losses) on inputs from related firms that were eliminated pursuant question III-8:
January-September 2009
January-September 2008
3
Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding
shipment quantities and values reported in Part II of this questionnaire.
4
COGS should include costs associated with internal consumption and transfers to related firms.
5
Please report funds received under this act in the period(s) in which they were received. Do not report these funds as an offset to
operating expenses.
2

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 17

PART III.--FINANCIAL INFORMATION--Continued
III-11. Asset values.--Report the total assets associated with the production, warehousing, and sale of
chloropicrin. If your firm does not maintain some or all of the specific asset data in the normal
course of business, please estimate it based upon some rational method (such as production, sales,
or costs) that is consistent with your cost allocations in the previous question. Your finished
goods inventory value should reconcile with the inventory quantity data reported in Part II.
Provide data as of the end of your three most recently completed fiscal years in chronological
order from left to right.
Value (in $1,000)
Fiscal years ended-Item
ASSETS associated with the
production, warehousing, and sale of
product:
1. Current assets:
A. Cash and equivalents
B. Accounts receivable, net
C. Inventories
D. Other (describe:

)

E. Total current assets (lines
1.A. through 1.D.)
2. Property, plant, and equipment
A. Original cost of property,
plant, and equipment
B. Less: Accumulated
depreciation
C. Equals: Book value of
property, plant, and
equipment
3. Other (describe:

)

4. Total assets (lines 1.E., 2.C.,
and 3)

III-12. Capital expenditures and research and development expenses.--Report your firm’s capital
expenditures and research and development expenses on chloropicrin. Provide data for your three
most recently completed fiscal years in chronological order from left to right, and for the
specified interim periods.
Value (in $1,000)
Fiscal years ended-Item
Capital expenditures
Research and
development expenses

January-September
2008
2009

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 18

PART IV.--PRICING AND MARKET FACTORS
Further information on this part of the questionnaire can be obtained from Joshua Levy (202-205-3236,
[email protected])
IV-1.

Contact information (Price).--Who should be contacted regarding the requested pricing and
related information?
Company contact:
Name and title
(
)
Phone number

E-mail address

PRICE DATA
This section requests quarterly quantity and value data, f.o.b. your U.S. point of shipment, for your
commercial shipments to unrelated U.S. customers since 2006 of the following products produced by
your firm.
Product 1.—Chloropicrin (100 to 96 percent pure) sold in a 180,000 pound rail car
container (base quantities on 100 percent equivalent)
Product 2.—Chloropicrin (100 to 96 percent pure) sold in a 50,000 pound ISO container
(base quantities on 100 percent equivalent)
Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include
U.S.-inland transportation costs. Total dollar values should reflect the final net amount paid to you
(i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 19

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-2.

Pricing data.--Report below the quarterly price data1 for pricing products2 produced and sold by
your firm.

Period of shipment

(Quantity in pounds, value in dollars)
Product 1
Quantity
Value

Product 2
Quantity
Value

2006:
January-March
April-June
July-September
October-December
2007:
January-March
April-June
July-September
October-December
2008:
January-March
April-June
July-September
October-December
2009:
January-March
April-June
July-September
1
Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of
returned goods), f.o.b. your U.S. point of shipment.
2
Pricing product definitions are provided on the first page of Part IV.
Note.--If your product does not exactly meet the product specifications but is competitive with the specified product,
provide a description of your product:
Product 1:
Product 2:

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 20

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-3. Price setting.-- How does your firm determine the prices that it charges for sales of chloropicrin
(check all that apply)? If your firm issues price lists, please include a copy of a recent price list with your
submission. If your price list is large, please only submit some sample pages.
Transaction by transaction

Contracts

Set price lists

Other--Please describe:

IV-4.

Discount policy.-- Please indicate and describe your firm’s discount policies (check all that
apply).
Quantity discounts

Annual total volume discounts

No discount policy

Other--Please describe:

IV-5.

IV-6.

Pricing terms for chloropicrin.-(a)

What are your firm’s typical sales terms for its U.S.-produced chloropicrin (e.g., 2/10 net
30 days)?
.

(b)

On what basis are your prices of domestic chloropicrin usually quoted? (check one)
F.o.b.--Please specify point:
Delivered

Contract versus spot.--Approximately what share of your firm’s sales of its U.S.-produced
chloropicrin in 2008 were on a (1) long-term contract basis (multiple deliveries for more than 12
months), (2) short-term contract basis (multiple deliveries up to and including 12 months), and (3)
spot sales basis (for a single delivery)?
Type of sale
Long-term contracts
Short-term contracts
Spot sales

Share of sales (percent)

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 21

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-7.

IV-8.

IV-9.

Long-term contact provisions.--If you sell on a long-term contract basis, please answer the
following questions with respect to provisions of a typical long-term contract.
(a)

What is the average duration of a contract?

(b)

Can prices be renegotiated during the contract period?

(c)

Does the contract fix quantity, price, or both?

(d)

Does the contract have a meet or release provision?

Yes

Quantity

No
Price

Yes

Both
No

Short-term contract provisions.--If you sell on a short-term contract basis, please answer the
following questions with respect to provisions of a typical short-term contract.
(a)

What is the average duration of a contract?

(b)

Can prices be renegotiated during the contract period?

(c)

Does the contract fix quantity, price, or both?

(d)

Does the contract have a meet or release provision?

Yes

Quantity

No
Price

Yes

Both
No

Lead times.--What is the average lead time between a customer’s order and the date of delivery
for your firm’s sales of your U.S.-produced chloropicrin?
Source

Share of sales in 2008

Lead time

From inventory
Produced to order
Total

100 %

IV-10. Shipping information.-(a)

What is the approximate percentage of the total delivered cost of chloropicrin that is
accounted for by U.S. inland transportation costs?
percent.

(b)

Who generally arranges the transportation to your customers’ locations? (check one)
Your firm or
purchaser

(c)

What proportion of your sales are delivered within 100 miles of your production facility?
percent. Within 101 to 1,000 miles?
percent. Over 1,000 miles?
percent.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 22

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-11. Geographical shipments.-- Based on the quantity of your firm’s U.S. shipments in 2008 as
reported in response to question II-8 above, please indicate the percentage share for which each of
the following geographic markets account. Please answer this question in reference to your sales
to ultimate delivery destinations to customers in the United States.
Share of U.S.
shipments in 2008
(in percent)

Geographic area
Northeast.–CT, ME, MA, NH, NJ, NY, PA, RI, and VT.
Midwest.–IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.
Southeast.–AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.
Central Southwest.–AR, LA, OK, and TX.
Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY.
Pacific Coast.–CA, OR, and WA.
Other.–All other markets in the United States not previously listed, including AK, HI,
PR, VI, among others.

Note.--These shares should be calculated from all reported U.S. shipments in 2008 (lines D, F, and H) from question II8.

IV-12. End uses.--Describe the end uses of the chloropicrin that you manufacture. For each end-use
product, what percentage of the total cost is accounted for by chloropicrin?
End use

Share of total cost (percent)

IV-13. Changes in end uses.--Have there been any changes in the end uses of chloropicrin since 2006?
No

Yes--Please describe.

IV-14. Anticipated changes in end uses.--Do you anticipate any changes in terms of the end uses of
chloropicrin in the future?
No

Yes--Please describe and identify the time period. Provide any underlying
assumptions, along with relevant portions of business plans or other
supporting documentation that address this issue.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 23

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-15. Substitutes.--Please list in order of importance any products that may be substituted for
chloropicrin. For each possible substitute product, please describe the degree of substitutability
and indicate whether changes in the price of the substitute affect the price for chloropicrin, and to
what degree, the length of any time lag of such an effect.

Substitute

Description

Have changes in the prices of this
substitute affected the price for
chloropicrin?

1.

No

Yes--Please explain.

2.

No

Yes--Please explain.

3.

No

Yes--Please explain.

4.

No

Yes--Please explain.

5.

No

Yes--Please explain.

IV-16. Changes in substitutes.--Have there been any changes in the number or types of products that
can be substituted for chloropicrin since 2006?
No

Yes--Please explain.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 24

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-17. Anticipated changes in substitutes.--Do you anticipate any changes in terms of the
substitutability of other products for chloropicrin in the future?
No

Yes--Please describe. Provide any underlying assumptions, along with
relevant portions of business plans or other supporting documentation
that address this issue.

IV-18. Raw materials.--To what extent have changes in the prices of raw materials affected your firm’s
selling prices for chloropicrin since 2006? Also discuss any anticipated changes in your raw
material costs in the future, identifying the time period(s) involved and the factor(s) that you
believe would be responsible for such changes. Provide any underlying assumptions, along with
relevant portions of business plans or other supporting documentation that address this issue.

IV-19. Changes in factors affecting supply.--Have any changes occurred in any other factors affecting
supply (e.g., changes in availability or prices of energy or labor; transportation conditions;
production capacity and/or methods of production; technology; export markets; or alternative
production opportunities) that affected the availability of U.S.-produced chloropicrin in the U.S.
market since 2006?
No

Yes--Please note the time period(s) of any such changes, the factors(s)
involved, and the impact such changes had on your shipment volumes
and prices.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 25

PART IV.--PRICING AND MARKET FACTORS--Continued
III-20. Changes in regulations.-(a)

Have any changes occurred in regulations that affect the availability of U.S. produced
chloropicrin in the U.S. market since 2006?
No

(b)

Yes--Please note the types of regulations, the timing of the changes in
regulations, and the impact of these regulations on your shipment
volumes and prices.

Have any changes occurred in regulations that affect the demand for U.S. produced
chloropicrin in the U.S. market since 2006?
No

Yes-- Please note the types of regulations, the timing of the changes
in regulations, and the impact of these regulations on your shipment
volumes and prices.

IV-21. Availability of supply (U.S.-produced).—
(a)

Do you anticipate any changes in terms of the availability of U.S.-produced chloropicrin
in the U.S. market in the future?
Increase

(b)

No change

Decrease

If you anticipate changes in supply, please identify the changes, including the time period
and the impact of such changes on shipment volumes and prices. Provide any underlying
assumptions, along with relevant portions of business plans or other supporting
documentation that address this issue.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 26

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-22. Availability of supply (nonsubject).--Has the availability of NONSUBJECT chloropicrin (i.e.,
chloropicrin imported from countries other than China) changed since 2006?
No

Yes--Please explain.

IV-23. Export constraints.--Describe how easily your firm can shift its sales of chloropicrin between
the U.S. market and alternative country markets. In your discussion, please describe any
contracts, other sales arrangements, or other constraints that would prevent or retard your firm
from shifting chloropicrin between the U.S. and alternative country markets within a 12-month
period. Provide any underlying assumptions, along with relevant portions of business plans or
other supporting documentation that address this issue.

IV-24. Product changes.--Have there been any significant changes in the product range, product mix, or
marketing (including sales over the internet) of chloropicrin since 2006?
No

Yes--Please describe and quantify if possible.

IV-25. Anticipated product changes.--Do you anticipate any changes in terms of the product range,
product mix, or marketing (including sales over the internet) of chloropicrin in the future?
Provide any underlying assumptions, along with relevant portions of business plans or other
supporting documentation that address this issue.
No

Yes--Please identify, including the time period.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 27

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-26. Demand trends.-(a)

How has the demand within the United States for chloropicrin changed since January 1,
2006? What principal factors affect changes in demand?
Increased

(b)

No Change

Decreased

Fluctuated

How has the demand outside the United States (if known) for chloropicrin changed since
January 1, 2006? What principal factors affect changes in demand?
Increased

No Change

Decreased

Fluctuated

IV-27. Anticipated demand trends.—
(a)

Do you anticipate any future changes in chloropicrin demand within the United States?
No

(b)

Yes--Please describe and identify the time period. Provide any
underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address
this issue.

Do you anticipate any future changes in chloropicrin demand outside the United States?
No

Yes--Please describe and identify the time period. Provide any
underlying assumptions, along with relevant portions of
business plans or other supporting documentation that address
this issue.

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 28

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-28. Price comparisons.--Please compare market prices of chloropicrin in U.S. and non-U.S. markets,
if known. Provide specific information as to time periods and regions for any price comparisons.

IV-29. Market studies.--Please provide as a separate attachment to this request any studies, surveys, etc.
that you are aware of that quantify and/or otherwise discuss chloropicrin supply (including
production capacity and capacity utilization) and demand in (1) the United States, (2) each of the
other major producing/consuming countries, including China, and (3) the world as a whole. Of
particular interest is such data from 2006 to the present and forecasts for the future.
IV-30. Barriers to trade.--Are your exports of chloropicrin subject to any tariff or non-tariff barriers to
trade in other countries?
No

Yes--Please list the countries and describe any such barriers and any
significant changes in such barriers that have occurred since 2006, or
that are expected to occur in the future.

IV-31. Interchangeability.--Is chloropicrin produced in the United States and in other countries
interchangeable (i.e., can they physically be used in the same applications)? Please indicate
below, using “A” to indicate that the products from a specified country-pair are always
interchangeable, “F” to indicate that the products are frequently interchangeable, “S” to indicate
that the products are sometimes interchangeable, “N” to indicate that the products are never
interchangeable, and “0” to indicate no familiarity with products from a specified country-pair.1
Country-pair

China

Other countries

United States
China
1

For any country-pair for which chloropicrin sometimes or never interchangeable, please explain the
factors that limit or preclude interchangeable use:

Business Proprietary
U.S. Producers’ Questionnaire - Chloropicrin from China (731-TA-130 (Third Review))

Page 29

PART IV.--PRICING AND MARKET FACTORS--Continued
IV-32. Factors other than price.--Are differences other than price (i.e., quality, availability,
transportation network, product range, technical support, etc.) between chloropicrin produced in
the United States and in other countries a significant factor in your firm’s sales of the products?
Please indicate below, using “A” to indicate that such differences are always significant, “F” to
indicate that such differences are frequently significant, “S” to indicate that such differences are
sometimes significant, “N” to indicate that such differences are never significant, and “0” to
indicate no familiarity with products from a specified country-pair.1
Country-pair

China

Other countries

United States
China
1

For any country-pair for which factors other than price always or frequently are a significant factor in
your firm’s sales of chloropicrin, identify the country-pair and report the advantages or disadvantages
imparted by such factors: